Liriodendrin

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Liriodendrin regulates lung inflammation, the phosphorylation of the NF-kB (p65) and expression of vascular endothelial growth factor (VEGF).

Liriodendrin regulates lung inflammation, the phosphorylation of the NF-kB (p65) and expression of vascular endothelial growth factor (VEGF). Liriodendrin has anti-inflammatory, antinociceptive, hypoglycemic activities. (In Vitro):When Liriodendrin was incubated for 24 h with human intestinal bacteria, two metabolites, (+)-syringaresinol-beta-D-glucopyranoside and (+)-syringaresinol, were produced. The metabolic time course of Liriodendrin was as follows: at early time, Liriodendrin was converted to (+)-syringaresinol-beta-D-glucopyranoside, and then (+)-syringaresinol.

——

Endocrinology/Hormones

ATPase

ATPase

——

——

573-44-4

742.7

C34H46O18

>98% (HPLC)

——

COc1cc(cc(OC)c1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1OC[C@@H]2[C@@H]1CO[C@@H]2c1cc(OC)c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)c(OC)c1

——

(-20℃)

With Ice Pack

≥ 2 years